MBX Biosciences Files IPO Amendment
Ticker: MBX · Form: S-1/A · Filed: Sep 9, 2024 · CIK: 1776111
Sentiment: neutral
Topics: ipo, sec-filing, biotech
TL;DR
MBX Biosciences IPO filing updated. Get ready for potential new biotech stock.
AI Summary
MBX Biosciences, Inc. filed an S-1/A amendment on September 9, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares under the Securities Act of 1933. Its principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
Why It Matters
This filing indicates MBX Biosciences is moving forward with its plan to become a publicly traded company, which could provide it with capital for research and development or expansion.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it pertains to an initial public offering, which inherently carries risks associated with new market entrants and the volatility of the biotech sector.
Key Numbers
- 333-281764 — SEC Registration Number (Identifies the specific registration for this offering.)
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- September 9, 2024 (date) — Filing date
- 333-281764 (registration_number) — SEC Registration Number
- P. Kent Hawryluk (person) — President and Chief Executive Officer
- Goodwin Procter LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is an amendment (Amendment No. 2) to the Form S-1 Registration Statement filed by MBX Biosciences, Inc. to register securities for its initial public offering.
When was this amendment filed?
This amendment was filed with the Securities and Exchange Commission on September 9, 2024.
What is the company's principal business address?
The company's principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
Who is the President and CEO of MBX Biosciences, Inc.?
P. Kent Hawryluk is the President and Chief Executive Officer of MBX Biosciences, Inc.
What is the company's state of incorporation?
MBX Biosciences, Inc. is incorporated in Delaware.
Filing Stats: 4,384 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-09-09 06:06:34
Key Financial Figures
- $14.00 — l public offering price will be between $14.00 and $16.00 per share. Prior to this o
- $16.00 — fering price will be between $14.00 and $16.00 per share. Prior to this offering, th
Filing Documents
- d790774ds1a.htm (S-1/A) — 2290KB
- d790774dex11.htm (EX-1.1) — 225KB
- d790774dex31.htm (EX-3.1) — 147KB
- d790774dex51.htm (EX-5.1) — 6KB
- d790774dex107.htm (EX-10.7) — 15KB
- d790774dex231.htm (EX-23.1) — 2KB
- d790774dexfilingfees.htm (EX-FILING FEES) — 21KB
- g790774dsp01.jpg (GRAPHIC) — 3KB
- g790774g00a06.jpg (GRAPHIC) — 71KB
- g790774g00m01.jpg (GRAPHIC) — 50KB
- g790774g00s44.jpg (GRAPHIC) — 161KB
- g790774g02s97.jpg (GRAPHIC) — 83KB
- g790774g14v41.jpg (GRAPHIC) — 89KB
- g790774g40a82.jpg (GRAPHIC) — 170KB
- g790774g43a01.jpg (GRAPHIC) — 112KB
- g790774g48m48.jpg (GRAPHIC) — 90KB
- g790774g59i17.jpg (GRAPHIC) — 89KB
- g790774g70y95.jpg (GRAPHIC) — 144KB
- g790774g72d51.jpg (GRAPHIC) — 78KB
- g790774g75h77.jpg (GRAPHIC) — 114KB
- g790774g75q33.jpg (GRAPHIC) — 58KB
- g790774g77b51.jpg (GRAPHIC) — 125KB
- g790774g80i17.jpg (GRAPHIC) — 90KB
- g790774g80w10.jpg (GRAPHIC) — 89KB
- g790774g82i98.jpg (GRAPHIC) — 74KB
- g790774g83a26.jpg (GRAPHIC) — 83KB
- g790774g84m86.jpg (GRAPHIC) — 167KB
- 0001193125-24-215436.txt ( ) — 5380KB
Risk factors
Risk factors 16 Special note regarding forward-looking statements 94
Use of proceeds
Use of proceeds 96 Dividend policy 98 Capitalization 99
Managements discussion and analysis of financial condition and results of operations
Managements discussion and analysis of financial condition and results of operations 104
Business
Business 122 Management 168
Executive compensation
Executive compensation 178 Certain relationships and related person transactions 192 Principal stockholders 197
Description of capital stock
Description of capital stock 200 Shares eligible for future sale 206 Material U.S. federal income tax considerations for non-U.S. holders 208
Underwriting
Underwriting 212 Legal matters 227 Experts 227 Where you can find more information 227 Index to financial statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surv